WallStreetZenWallStreetZen

NASDAQ: TRIB
Trinity Biotech PLC Stock

$0.70-0.01 (-1.41%)
Updated Sep 22, 2023
TRIB Price
$0.70
Fair Value Price
N/A
Market Cap
$26.68M
52 Week Low
$0.63
52 Week High
$1.41
P/E
N/A
P/B
-4.03x
P/S
0.51x
PEG
N/A
Dividend Yield
N/A
Revenue
$70.83M
Earnings
-$34.54M
Gross Margin
28.7%
Operating Margin
-13.47%
Profit Margin
-48.8%
Debt to Equity
-14.77
Operating Cash Flow
N/A
Beta
0.44
Next Earnings
Nov 9, 2023
Ex-Dividend
N/A
Next Dividend
N/A

TRIB Overview

Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.

Zen Score

Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how TRIB scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

TRIB's profit margin has decreased (-33.1%) in the last year from (-15.7%) to (-48.8%)
Profit Margin Growth Financials
TRIB's short-term assets ($58.26M) exceed its short-term liabilities ($16.15M)
Short-term Liabilities Financials
TRIB's long-term liabilities ($81.63M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
There are 35 more TRIB due diligence checks available for Premium users.

Be the first to know about important TRIB news, forecast changes, insider trades & much more!

TRIB News

Valuation

TRIB fair value

Fair Value of TRIB stock based on Discounted Cash Flow (DCF)
Price
$0.70
Fair Value
$1.04
Undervalued by
32.69%

TRIB price to earnings (PE)

For valuing profitable companies with steady earnings
Company
0x
Industry
25.9x
Market
14.52x

TRIB price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
-4.03x
Industry
3.92x

TRIB's financial health

Profit margin

Revenue
$14.8M
Net Income
-$5.8M
Profit Margin
-39.2%
TRIB's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$91.2M
Liabilities
$97.8M
Debt to equity
-14.77
TRIB's short-term assets ($58.26M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TRIB's long-term liabilities ($81.63M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TRIB's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TRIB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
N/A
Investing
N/A
Financing
N/A

TRIB vs Diagnostic & Research Stocks

TickerMarket Cap1d %P/EP/B
TRIB$26.68M-0.71%N/A-4.03x
OCX$26.24M-1.12%-0.31x0.60x
CHEK$23.22M-1.98%-1.18x0.77x
CNTG$31.46M+3.64%-0.72x-1.90x
PMD$21.13M+0.55%-10.82x2.32x

Trinity Biotech Stock FAQ

What is Trinity Biotech's quote symbol?

(NASDAQ: TRIB) Trinity Biotech trades on the NASDAQ under the ticker symbol TRIB. Trinity Biotech stock quotes can also be displayed as NASDAQ: TRIB.

If you're new to stock investing, here's how to buy Trinity Biotech stock.

What is the 52 week high and low for Trinity Biotech (NASDAQ: TRIB)?

(NASDAQ: TRIB) Trinity Biotech's 52-week high was $1.41, and its 52-week low was $0.63. It is currently -50.42% from its 52-week high and 10.76% from its 52-week low.

How much is Trinity Biotech stock worth today?

(NASDAQ: TRIB) Trinity Biotech currently has 152,430,284 outstanding shares. With Trinity Biotech stock trading at $0.70 per share, the total value of Trinity Biotech stock (market capitalization) is $26.68M.

Trinity Biotech stock was originally listed at a price of $7.88 in Dec 31, 1997. If you had invested in Trinity Biotech stock at $7.88, your return over the last 25 years would have been -91.12%, for an annualized return of -9.23% (not including any dividends or dividend reinvestments).

How much is Trinity Biotech's stock price per share?

(NASDAQ: TRIB) Trinity Biotech stock price per share is $0.70 today (as of Sep 22, 2023).

What is Trinity Biotech's Market Cap?

(NASDAQ: TRIB) Trinity Biotech's market cap is $26.68M, as of Sep 26, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Trinity Biotech's market cap is calculated by multiplying TRIB's current stock price of $0.70 by TRIB's total outstanding shares of 152,430,284.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.